Thanks to your immune system, you already have the power to fight cancer inside of you! Although the immune system is usually associated with protecting us from viruses, bacteria, and other disease-causing organisms, it actually has a big role in helping fight cancer by being able to recognize and kill cancer cells.
A major function of the immune system is to recognize foreign objects (viruses, bacteria, parasites, splinters, and anything else that isn’t supposed to be in your body) and destroy them. Immune cells do this by recognizing specific targets on the surface of the object. Cancer cells are abnormal and may be recognized as ‘foreign’ by immune cells. Immune cells can then kill these cancer cells.
Topics discussed on this page:
- Why do people get cancer?
- Immune system- cancer cell battles
- How can cancer cell defenses be overcome?
Unfortunately, the immune system is also deeply involved in the development of cancer. While this is certainly not something that is good for the person, the cells are not 'thinking' about what they are doing, and are only really doing what they are being told to do. You can learn more about that here:
A major function of the immune system is to recognize foreign objects (viruses, bacteria, parasites, splinters, and anything else that isn’t supposed to be in your body) and destroy them. Immune cells do this by recognizing specific targets on the surface of the item to be destroyed. Cancer cells are abnormal and may be recognized as ‘foreign’ by immune cells. Immune cells recognize small molecular ‘flags’ associated with tumor cells (called tumor specific antigens (TSAs) or tumor associated antigens (TAAs)). Immune cells can then kill these cancer cells.
Note: An antigen can be defined as anything the immune system can recognize. It is a general term. Antigens can be proteins, sugars, lipids, nucleic acids, or hybrid molecules. Most antigens are proteins.
If the immune system is able to recognize and kill cancer cells, why do people get cancer?
It is thought that most cancers are caught very early and eliminated by the immune system. The cancers that survive have to be able to evade the immune system. It turns out that there are several ways that cancer cells avoid being recognized and killed. These include:
- Cancer cells form from normal cells.Because cancer arises from a person’s own cells, it’s trickier for the immune system to recognize cancer cells than to identify a truly foreign invader like a virus.
- Cancer cells with the most targets on them are most easily killed by the immune system. This sounds like a good thing, and it can make tumors shrink, but after a while, the cancer cells that are left have less targets on their surface. Those with the least amount of target antigens on their surface have the best chance of surviving, and tend to take over, making the cancer resistant to immune cells. It is similar to treating a lawn with weed killer. Any weeds that are resistant will survive and grow. After that, the weed killer will not work anymore. The immune system accidentally ‘selects’ for cancer cells that it can’t recognize.
- Cancer cells can hijack normal control systems to turn the immune system ‘off’ in and around the tumor. To keep the immune system under control, there are several controls (like ‘on-off’ switches) that work to regulate the activity of immune cells. Some cancer cells are able to flip that switch, turning the immune system off in the area around and in the tumor. Treatments designed to reverse this are very promising and are described more below.
- Cancer cells can evade the immune system by making less of the ‘self’ signals that immune cells use to recognize defective or infected cells.Cancer proteins can be shown to the immune system by being stuck to cellular versions of flagpoles. By taking down the poles, cancer cells prevent this from happening and are able to avoid being recognized and killed.123
The battle between the immune system and cancer is complex and can last for many years. It is likely that most cancers are eliminated by the immune system at very early stages, before there would be any evidence of their existence. It is only the cancers that are able to avoid the immune system that can grow to become dangerous.
How does the immune system kill cancer cells?
The immune system is divided up like a military organization, with different cells armed with different weapons to attack different kinds of targets.
Natural killer (NK) cells are able to recognize proteins on a tumor cell’s surface, They release proteins that punch holes in the target cell membrane, and cause cell death.
Other cells, (macrophages and dendritic cells) may join in, and release cell-signaling proteins (cytokines) that recruit and ‘activate’ T-cells. Stimulated T-cells can directly kill cancer cells or recruit yet another type of immune cell, B-cells. B-cells produce proteins (antibodies) that can stick to targets on the cancer cells. This further intensifies the response and can lead to killing of the cancer cells.4567
How can a cancer cell shut down the immune system?
As mentioned previously, the immune system is a powerful weapon. Not surprisingly, there are controls in place to turn off the system when it is no longer needed. One ‘off switch’ is called programmed death ligand 1 (PD-L1). It is a protein that is normally found on immune cells called macrophages. PD-L1 binds to another protein, PD-1, which is found on the surface of T-cells When these two protein come into contact with each other the T-cells are ‘told’ to stop attacking.
If a cancer cell has PD-L1 on its surface, T-cells that come into contact with that cell are likely to shut down their defensive activities. This leads to cancer cell survival.
An additional signal that tells T-cells to stop attacking cancer cells is sent by another pair of proteins, CTLA-4 and B7-1. Like PD-1, CTLA-4 is found on the surface of T cells. Like the PD-1/PD-L1 interaction, when CTLA-4 binds to its partner, the T-cell becomes inactive.8910
Many researchers are working to develop treatments that will ‘wake up’ and activate the immune system in cancer patients. Drugs that target immune-evasion tactics used by cancer have produced some very exciting results and are being very actively studied.
Treatments to stimulate the immune system fall into a few different categories.
1. General immune activation
There are several proteins that work to cause general immune activation. These cell to cell signals (cytokines) turn up the immune activity in the body. They are not specific to any particular target or cancer. The idea behind using these to treat cancer is that the immune system can kill cancer if it is active. These signals are like putting a military on ‘high alert’. Examples of immune stimulating cytokines are alpha-interferon (α-IFN) and interleukin 2 (IL-2). These proteins can be man-made, and are approved treatments for some forms of cancer.11121314
2. Checkpoint blockers
These drugs work to ‘turn on’ immune cells that have been switched off by one of the protein interactions described previously.
One of the first cancer immunotherapies to become FDA-Approved is ipilimumab (brand name Yervoy®). The drug is actually an antibody. Antibodies are proteins that very specifically bind to targets. Antibodies neutralize the target and sometimes signal other cells to destroy the target. Yervoy helps prolong the immune response against cancer by binding to and stopping the function of CTLA-4. If CTLA-4 binding to B7-1is prevented, a more sustained immune response can occur.
Yervoy® is approved to treat melanoma because clinical studies of Yervoy® showed that it extended survival for melanoma patients.15 Yervoy® is currently undergoing clinical studies to test its efficacy in treating lung cancer , bladder cancer , and prostate cancer.161718
Pembrolizumab (Keytruda® ) is an antibody drug that binds to PD-1, blocking the interaction between PD-1 and PD-L1. This treatment is approved for use in melanoma patients 19 and received 'breakthrough therapy' designation from the FDA as a treatment for some forms of lung cancer.20
Another anti-PD-1 antibody, nivolumab (brand name - Opdivo®), is approved in the U.S. for use in melanoma and non-small cell lung cancer.2122 Opdivo® works like Keytruda®; by blocking the PD-1/PD-L1 interaction, it allows T cells to stay active, even if tumor cells have PD-L1 on their surface. Testing against several additional cancers is underway.23
Check for active trials. (Opens in a new window.)
Another antibody immunotherapy is the anti-PD-L1 antibody MPDL3280A. This antibody is similar to Opdivo®, except it sticks to PD-1’s partner, PD-L1. The results are the same, activation of the immune system. Clinical trials are currently ongoing.
Check for active trials. (Opens in a new window.)
The image to the right shows the interaction between a cancer cell and a T cell, a type of immune system cell. When the the PD-1/PD-L1 interaction occurs, it shuts down the activity of that T cell. This limits the ability of the body to fight cancer. The antibody drugs, prevent that from happening by sticking to one of the partners. The diagram shows an antibody stuck to the PD-1 protein. This is the way that Keytruda® and Opdivo® work.
3. Cancer vaccines
Another approach is to try to boost the immune response to cancer by using cancer cell proteins to stimulate the immune system. Individual proteins, or mixtures of proteins can be used to teach the immune cells what they should be looking for. This is very similar to the way that vaccines work to prevent diseases like mumps and measles.
There are several approaches to cancer vaccines being studied. These are covered in a separate treatment section.
4. Chimeric antigen receptor (CAR) T cell therapy takes the idea behind cancer vaccines one step further. Instead of activating antigen presenting cells against the person’s cancer, the person’s T cells are modified to specifically attack cancer cells. This is done by genetically modifying the patient’s T cells to recognize proteins on the surface of cancer cells.2425 The results have been very exciting. A clinical trial of CAR T cells used against B cell acute lymphocytic leukemia (ALL) yielded an 88% overall complete response rate.26
On July 12, 2017, the FDA advisory committee unanimously voted to recommend the approval of a CAR T-cell therapy for children and young adults with acute lymphoblastic leukemia (ALL) that has relapsed or resisted treatment.27 On August 30, 2017 the FDA approved the cancer treatment Kymriah, the first gene therapy legally available in the United States. It was approved to treat patients under the age of 25 with certain types of B-cell acute lymphoblastic leukemia (ALL).28
- 1. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015 Mar 25. pii: S1044-579X(15)00019-X [Epub ahead of print] [PUBMED]
- 2. Seliger B. Strategies of tumor immune evasion. BioDrugs. 2005;19(6):347-54. [PUBMED]
- 3. Poggi A, Musso A, Dapino I, Zocchi MR. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett. 2014 May-Jun;159(1-2):55-72. Epub 2014 Mar 20. [PUBMED]
- 4. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004 Aug;21(2):137-48. [PUBMED]
- 5. Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010 Apr;22(2):215-22. Epub 2010 Mar 6. [PUBMED]
- 6. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1-50. [PUBMED]
- 7. Bachanova V, Miller JS. NK cells in therapy of cancer. Crit Rev Oncog. 2014;19(1-2):133-41. [PUBMED]
- 8. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015 Mar 4. pii: S0161-5890(15)00049-8. [Epub ahead of print] [PUBMED]
- 9. Zamarin D, Postow MA. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther. 2015 Jun;150:23-32. Epub 2015 Jan 10. [PUBMED]
- 10. Pico de Coaña Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015 Jun 16. [Epub ahead of print] [PUBMED]
- 11. Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity. 2010 Apr;43(3):204-9. [PUBMED]
- 12. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007 Jun-Jul;89(6-7):884-93. Epub 2007 Apr 21. [PUBMED]
- 13. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014 Jun 15;192(12):5451-8 [PUBMED]
- 14. Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90. Epub 2014 Aug 1. [PUBMED]
- 15. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. Epub 2010 Jun 5. [PUBMED]
- 16. Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Mar 2;4(4):e1008814. eCollection 2015. [PUBMED]
- 17. Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. Ann Pharmacother. 2015 May 19. [Epub ahead of print] [PUBMED]
- 18. Villaruz LC, Kalyan A, Zarour H, Socinski MA. Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014 Feb;3(1):2-14. [PUBMED]
- 19. FDA approves Keytruda for advanced melanoma. U.S. Food and Drug Administration website. Published September 4, 2014. Updated September 10, 2014. Accessed September 13, 2014. [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm.]
- 20. Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer 11/27/2014 [http://www.mercknewsroom.com/news-release/oncology-newsroom/merck-receives-fda-breakthrough-therapy-designation-keytruda-pembroli]
- 21. FDA approves Opdivo for advanced melanoma (FDA News Release) [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm]
- 22. FDA expands approved use of Opdivo to treat lung cancer (FDA News Release) [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm436534.htm]
- 23. Clinical Trials Search Results for Opdivo® [http://www.cancer.gov/about-cancer/treatment/clinical-trials/search/results?protocolsearchid=14278803]
- 24. Chakravarti D, Wong WW. Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol. 2015 Jun 15. pii: S0167-7799(15)00110-9. [Epub ahead of print] [PUBMED]
- 25. Sharpe M, Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech. 2015 Apr;8(4):337-350. Epub 2015 Apr 1. [PUBMED]
- 26. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25 [PUBMED]
- 27. Mika, Aggie. "FDA Votes Yes on CAR T-Cell Therapy." The Scientist (2017). [THE SCIENTIST]
- 28. FDA approves Kymriah for the treatment of refractory B-cell ALL in patients under 25 years of age. [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm]